Tran Charles W, Saibil Samuel D, Le Bihan Thierry, Hamilton Sara R, Lang Karl S, You Han, Lin Amy E, Garza Kristine M, Elford Alisha R, Tai Kelly, Parsons Michael E, Wigmore Kip, Vainberg Mitchell G, Penninger Josef M, Woodgett James R, Mak Tak W, Ohashi Pamela S
The Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, Toronto, Ontario M5G 2M9, Canada.
Department of Immunology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
J Immunol. 2017 Dec 15;199(12):4056-4065. doi: 10.4049/jimmunol.1600396. Epub 2017 Nov 6.
The decision between T cell activation and tolerance is governed by the spatial and temporal integration of diverse molecular signals and events occurring downstream of TCR and costimulatory or coinhibitory receptor engagement. The PI3K-protein kinase B (PKB; also known as Akt) signaling pathway is a central axis in mediating proximal signaling events of TCR and CD28 engagement in T cells. Perturbation of the PI3K-PKB pathway, or the loss of negative regulators of T cell activation, such as the E3 ubiquitin ligase Cbl-b, have been reported to lead to increased susceptibility to autoimmunity. In this study, we further examined the molecular pathway linking PKB and Cbl-b in murine models. Our data show that the protein kinase GSK-3, one of the first targets identified for PKB, catalyzes two previously unreported phosphorylation events at Ser and Ser of Cbl-b. GSK-3 inactivation by PKB abrogates phosphorylation of Cbl-b at these two sites and results in reduced Cbl-b protein levels. We further show that constitutive activation of PKB in vivo results in a loss of tolerance that is mediated through the downregulation of Cbl-b. Altogether, these data indicate that the PI3K-PKB-GSK-3 pathway is a novel regulatory axis that is important for controlling the decision between T cell activation and tolerance via Cbl-b.
T细胞激活与耐受之间的抉择受TCR以及共刺激或共抑制受体结合后下游发生的多种分子信号和事件的时空整合所调控。PI3K-蛋白激酶B(PKB;也称为Akt)信号通路是介导T细胞中TCR和CD28结合的近端信号事件的核心轴。据报道,PI3K-PKB通路的扰动或T细胞激活负调节因子(如E3泛素连接酶Cbl-b)的缺失会导致自身免疫易感性增加。在本研究中,我们在小鼠模型中进一步研究了连接PKB和Cbl-b的分子途径。我们的数据表明,蛋白激酶GSK-3是PKB确定的首批靶标之一,它催化Cbl-b的Ser和Ser位点发生两个此前未报道的磷酸化事件。PKB使GSK-3失活会消除Cbl-b在这两个位点的磷酸化,并导致Cbl-b蛋白水平降低。我们进一步表明,体内PKB的组成性激活会导致耐受性丧失,这是通过Cbl-b的下调介导的。总之,这些数据表明PI3K-PKB-GSK-3通路是一条新的调节轴,对于通过Cbl-b控制T细胞激活与耐受之间的抉择很重要。